Aurora BioPharma

Aurora BioPharma is built on the single mission of revolutionizing cancer treatment through the use of the human immune system. Aurora is developing cutting-edge cancer immunotherapies, a form of adoptive cell transfer known as Chimeric Antigen Receptor (CAR) T-cell therapy. The blood of cancer patients is drawn, their T cells extracted from their white blood cells, genetically edited to express CARs specific to that type of cancer cell, and then reinfused back into the patient to target and kill cancer cells. The U.S. Food and Drug Administration (FDA) has granted CAR T-cell therapy Breakthrough Therapy designation for the treatment of pediatric and adult acute lymphoblastic leukemia and non-Hodgkin lymphoma.